Holen Sie sich die Stockscreener-App
23.98
1.84%
-0.45
Handel nachbörslich:
20.27
-3.71
-15.47%
Schlusskurs vom Vortag:
$24.43
Offen:
$23.63
24-Stunden-Volumen:
218.86K
Relative Volume:
3.44
Marktkapitalisierung:
$264.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-14.66%
1M Leistung:
+15.85%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$19.57
$24.00
1-Wochen-Bereich:
$19.57
$28.78
52-Wochen-Spanne:
$11.17
$29.27
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
125 STRAFFORD AVE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
23.98 | 264.23M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Rare Disease Breakthrough: Palvella CEO Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MSN
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - The Manila Times
Groundbreaking Phase 3 Results: First-Ever Treatment for Rare Lymphatic Disease Heads to Major Congress - Stock Titan
Palvella Therapeutics (NASDAQ:PVLA) Given “Buy” Rating at HC Wainwright - Defense World
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
Stifel maintains $45 target on Palvella Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains $45 target on Palvella Therapeutics stock - Investing.com
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus By Investing.com - Investing.com South Africa
Earnings call transcript: Palvella Therapeutics Q4 2024 reveals strategic focus - Investing.com
Palvella Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palvella Therapeutics Reports 2024 Financial Results and Updates - TipRanks
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Palvella Therapeutics to Announce 2024 Financial Results and Host Investor Call on March 31, 2025 - MSN
Palvella Therapeutics (PVLA) to Release Earnings on Monday - Defense World
Palvella Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $43.20 - Defense World
Palvella Therapeutics (PVLA) Projected to Post Earnings on Monday - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Stifel Nicolaus - Defense World
Is Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025? - Insider Monkey
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target - MarketScreener
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Jones Trading - Defense World
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target By Investing.com - Investing.com Canada
Jones Trading Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Stifel initiates Palvella Therapeutics with a buy, $45 target By Investing.com - Investing.com Canada
Stifel analysts initiate Palvella Therapeutics stock with Buy, $45 target - Investing.com
Stifel initiates Palvella Therapeutics with a buy, $45 target - Investing.com
Palvella Therapeutics initiated with a Buy at Stifel - TipRanks
Palvella Therapeutics (PVLA) Projected to Post Earnings on Thursday - Defense World
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - GlobeNewswire
Palvella Therapeutics, Inc. Scheduled to Report Full Year 2024 Financial Results on March 31, 2025 - Nasdaq
Rare Disease Leader Palvella Therapeutics Unveils 2024 Financial Performance March 31 - StockTitan
Lucid Capital sets $49 target on Palvella Therapeutics stock By Investing.com - Investing.com UK
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well - Yahoo Finance
Palvella Therapeutics Insider Confidence Rewarded, Stock Hits US$308m Market Cap - simplywall.st
Pieris Pharmaceuticals stock soars to 52-week high of $29.01 - Investing.com
PavellaUndiscovered Biotechnology Stock - TradingView
PalvellaUndiscovered Biotechnology Stock - Barchart
Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Scotiabank - Defense World
Scotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Palvella stock to Sector Outperform, $50 target - Investing.com
Scotiabank sets Palvella stock to Sector Outperform, $50 target By Investing.com - Investing.com UK
Palvella Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Pieris Pharmaceuticals stock hits 52-week high at $22.56 By Investing.com - Investing.com Canada
Pieris Pharmaceuticals stock hits 52-week high at $22.56 - Investing.com
Palvella Therapeutics Enhances Investor Relations with New Presentation - TipRanks
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):